Cascadian Therapeutics Inc.
Cascadian Therapeutics is a clinical-stage biopharmaceutical company developing novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. Our lead product candidate is tucatinib, an oral, HER2-selective small molecule TKI. We are conducting a randomized, double-blind, controlled pivotal trial called HER2CLIMB, comparing tucatinib vs. placebo in combination with capecitabine and trastuzumab in patients with locally advanced or metastatic HER2+ breast cancer with and without brain metastases. Details on HER2CLIMB can be found at ClinicalTrials.gov.